Zavicefta and Aztreonam Dosing
For adults with normal renal function, administer Zavicefta (ceftazidime-avibactam) 2.5 g IV every 8 hours infused over 2-3 hours, and aztreonam 1-2 g IV every 6-8 hours.
Standard Adult Dosing
Zavicefta (Ceftazidime-Avibactam)
The standard dose is 2.5 g (ceftazidime 2 g/avibactam 0.5 g) IV every 8 hours, infused over 2-3 hours 1. This regimen is recommended for:
- Carbapenem-resistant Enterobacterales (CRE) bloodstream infections 1
- Complicated urinary tract infections (cUTI) due to CRE 1
- Complicated intra-abdominal infections (cIAI) when combined with metronidazole 1
The 3-hour infusion is particularly important for optimizing pharmacodynamic target attainment, especially in critically ill patients or those with preserved renal function 2, 3.
Aztreonam
Standard dosing ranges from 1-2 g IV every 6-8 hours 4, 5:
- Moderate infections: 1 g every 8-12 hours
- Severe/life-threatening infections: 2 g every 6-8 hours
- Pseudomonas aeruginosa infections: 2 g every 6-8 hours is recommended at initiation 5
The maximum recommended daily dose is 8 g 5.
Renal Impairment Adjustments
Zavicefta Dose Adjustments
Dosing must be adjusted based on creatinine clearance (CrCl):
- CrCl 31-50 mL/min: 1.25 g (1 g/0.25 g) every 8 hours
- CrCl 16-30 mL/min: 0.94 g (0.75 g/0.19 g) every 12 hours
- CrCl 6-15 mL/min: 0.94 g (0.75 g/0.19 g) every 24 hours
- CrCl ≤5 mL/min: 0.94 g (0.75 g/0.19 g) every 48 hours
These modified dosage adjustments represent a 50% increase in total daily dose compared to original recommendations, implemented to reduce the risk of subtherapeutic exposures during rapidly improving renal function 6.
For hemodialysis patients: Administer after dialysis sessions, as both ceftazidime and avibactam are significantly cleared by hemodialysis 7.
Aztreonam Dose Adjustments
After an initial loading dose of 1-2 g, adjust maintenance dosing 5:
- CrCl 10-30 mL/min: Give half the usual dose at the usual interval (e.g., 1 g every 8 hours becomes 0.5 g every 8 hours)
- CrCl <10 mL/min or hemodialysis:
- Maintenance dose: one-fourth of usual initial dose at usual intervals
- After each hemodialysis: Give one-eighth of the initial dose as a supplement 5
For simplified hemodialysis dosing, 1-2 g administered once daily after hemodialysis achieves adequate target attainment for MICs up to 4-8 mg/L respectively 8. Thrice-weekly dosing should be avoided except in non-severe infections with MICs ≤0.5 mg/L 8.
Special Combination: Zavicefta + Aztreonam for MBL-Producing CRE
For metallo-β-lactamase (MBL)-producing CRE, co-administer both drugs simultaneously 9, 10:
- Normal renal function (CrCl >90 mL/min): Zavicefta 2.5 g + aztreonam 2 g, both every 6 hours provides higher joint probability of target attainment than every 8 hours dosing 10
- Reduced renal function (CrCl ≤90 mL/min): Use renal-adjusted doses for both agents; most regimens maintain ≥90% joint target attainment under conventional targets 10
This combination is necessary because avibactam does not inhibit MBLs, but co-administration with aztreonam restores activity against MBL-producing organisms 9, 10.
Critical Considerations
Infusion Duration
- Extended infusions (2-3 hours) are strongly preferred over shorter infusions for Zavicefta, particularly in patients with normal renal function, to optimize time above MIC 2, 3
- Shortening infusion to 1 hour reduces target attainment in patients with CrCl >80 mL/min 10
Monitoring Requirements
- Therapeutic drug monitoring (TDM) is essential during acute kidney injury recovery, as rapid renal function improvement can lead to subtherapeutic levels 7
- Monitor renal function closely; dose adjustments should follow the pace of renal recovery 7
- In elderly patients, estimate creatinine clearance rather than relying solely on serum creatinine 5
Neurotoxicity Risk
- Ceftazidime trough concentrations >80 mg/L are associated with neurotoxicity risk 2
- Risk remains low across renal strata with appropriate dose adjustments 10
Continuous Renal Replacement Therapy (CRRT)
- Both aztreonam and avibactam are significantly cleared by CVVHDF 7
- Filter type matters: Oxiris filters produce substantially lower drug concentrations than HF12 filters 7
- Standard severe impairment dosing may be insufficient; TDM-guided individualization is mandatory 7
Common Pitfall
Suboptimal Zavicefta exposure (from inadequate renal dose adjustment or shortened infusions) can drive sequential blaKPC mutations, leading to treatment failure and persistent infection 11. Always use the full recommended dose with appropriate infusion duration, and adjust promptly for changing renal function.